Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists
- 1 March 2008
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 73 (3) , 789-800
- https://doi.org/10.1124/mol.107.042101
Abstract
In addition to being an important receptor in leukocyte activation and mobilization, CCR5 is the essential coreceptor for human immunodeficiency virus (HIV). A large number of small-molecule CCR5 antagonists have been reported that show potent activities in blocking chemokine function and HIV entry. To facilitate the design and development of next generation CCR5 antagonists, docking models for major classes of CCR5 antagonists were created by using site-directed mutagenesis and CCR5 homology modeling. Five clinical candidates: maraviroc, vicriviroc, aplaviroc, TAK-779, and TAK-220 were used to establish the nature of the binding pocket in CCR5. Although the five antagonists are very different in structure, shape, and electrostatic potential, they were able to fit in the same binding pocket formed by the transmembrane (TM) domains of CCR5. It is noteworthy that each antagonist displayed a unique interaction profile with amino acids lining the pocket. Except for TAK-779, all antagonists showed strong interaction with Glu283 in TM 7 via their central basic nitrogen. The fully mapped binding pocket of CCR5 is being used for structure-based design and lead optimization of novel anti-HIV CCR5 inhibitors with improved potency and better resistance profile.Keywords
This publication has 44 references indexed in Scilit:
- Discovery of a Piperidine-4-carboxamide CCR5 Antagonist (TAK-220) with Highly Potent Anti-HIV-1 ActivityJournal of Medicinal Chemistry, 2006
- GlaxoSmithKline ends aplaviroc trialsAIDS, 2006
- Development of a Novel Dual CCR5-Dependent and CXCR4-Dependent Cell-Cell Fusion Assay System with Inducible gp160 ExpressionSLAS Discovery, 2006
- Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 ActivityAntimicrobial Agents and Chemotherapy, 2005
- Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1Nature Medicine, 2005
- An overview of the determinants of CCR5 and CXCR4 co-receptor functionJournal of General Virology, 2001
- A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5Proceedings of the National Academy of Sciences, 2000
- The Protein Data BankNucleic Acids Research, 2000
- Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling toolJournal of Molecular Biology, 1997
- Prediction of Protein Three-dimensional Structures in Insertion and Deletion Regions: A Procedure for Searching Data Bases of Representative Protein Fragments Using Geometric Scoring CriteriaJournal of Molecular Biology, 1995